1. Market Research
  2. > Terumo Corporation (4543) - Financial and Strategic SWOT Analysis Review

Terumo Corporation (4543) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Terumo Corporation (Terumo) is a medical technology company. It manufactures and sells a wide range of medical care products including hospital and medical products, equipment and pharmaceuticals. Its major products include vascular interventional products, cardiovascular surgical systems, artificial vascular grafts, blood transfusion systems, infusions systems, nutritious food, diabetes monitoring and treatment devices, cancer pain management systems, home oxygen therapy systems and consumer healthcare products. The company conducts its operations in three divisions, namely, General Hospital business, Cardiac and Vascular business, and Blood Management business. Terumo conducts its operations through subsidiaries and associate companies in Japan, Europe, Americas and Asia-Pacific. The company is headquartered in Tokyo, Japan.

Terumo Corporation Key Recent Developments

Sep 02, 2015: Terumo's Autologous Skeletal Myoblast Sheets Are the First to Be Approved as a Cellular or Tissue-based Products in Japan by a Council of the Ministry of Health, Labour and Welfare
May 19, 2015: Terumo Announces CE Mark Clearance for Bioresorbable Scaffold Developed by Arterial Remodeling Technologies
Apr 17, 2015: Regarding the Result of Inspection at Terumo CVS Ann Arbor Plant
Apr 06, 2015: Terumo and Olympus Expand Interventional System Business Partnership
Mar 19, 2015: Scientists at Nelson Laboratories Discover Extractable Positive Control for In Vitro Skin Irritation Testing of Medical Devices

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Terumo Corporation (4543) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2

Section 1 - About the Company 6
Terumo Corporation - Key Facts 6
Terumo Corporation - Key Employees 7
Terumo Corporation - Key Operational Employees 10
Terumo Corporation - Major Products and Services 11
Terumo Corporation - Medical Equipment Pipeline Products Data 13
Terumo Corporation Pipeline Products by Equipment Type 13
Terumo Corporation Pipeline Products by Development Stage 14
Terumo Corporation - History 16
Terumo Corporation - Company Statement 23
Terumo Corporation - Locations And Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Joint Venture 28
Section 2 - Company Analysis 29
Terumo Corporation - Business Description 29
Business Description - Blood Transfusion Products 29
Blood Transfusion Products - Overview 29
Blood Transfusion Products - Financials 29
Business Description - Cardiac and Vascular Products 29
Cardiac and Vascular Products - Overview 29
Cardiac and Vascular Products - Financials 29
Business Description - General Hospital Products 29
General Hospital Products - Overview 29
General Hospital Products - Financials 30
Terumo Corporation - Corporate Strategy 31
Terumo Corporation - SWOT Analysis 32
SWOT Analysis - Overview 32
Terumo Corporation - Strengths 32
Strength - Improving Financial Position 32
Strength - Cardiac and Vascular Franchise 32
Strength - Strong Presence in International Markets 32
Terumo Corporation - Weaknesses 33
Weakness - Product Safety Concerns 33
Weakness - Substantial Debt 33
Terumo Corporation - Opportunities 34
Opportunity - The US FDA 510(k) Clearances 34
Opportunity - Increasing Cardiovascular Diseases 34
Opportunity - Strategic Initiatives 34
Terumo Corporation - Threats 36
Threat - Rise in Raw Material Prices 36
Threat - Intense Competition 36
Threat - Rapid Technological Changes 36
Threat - Stringent Government Regulations 36
Terumo Corporation - Key Competitors 37
Section 3 - Company Financial Ratios 38
Financial Ratios - Capital Market Ratios 38
Financial Ratios - Annual Ratios 39
Performance Chart 41
Financial Performance 41
Financial Ratios - Interim Ratios 42
Financial Ratios - Ratio Charts 43
Section 4 - Company's Lifesciences Financial Deals and Alliances 44
Terumo Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 44
Terumo Corporation, Medical Equipment, Deals By Type, 2010 to YTD 2016 45
Terumo Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 46
Terumo Corporation, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 47
Terumo Corporation, Recent Deals Summary 48
Section 5 - Company's Recent Developments 49
Jun 10, 2016: FDA Lifts All Remaining Shipping Restrictions at Terumo Cardiovascular Systems' Ann Arbor Facility 49
Mar 02, 2016: NICE recommends new sickle cell treatment device that could save the NHS millions 50
Sep 02, 2015: Terumo's Autologous Skeletal Myoblast Sheets Are the First to Be Approved as a Cellular or Tissue-based Products in Japan by a Council of the Ministry of Health, Labour and Welfare 51
Jul 01, 2015: OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo 52
Jun 01, 2015: MicroVention to Locate Its New 205,000 Square-Foot Worldwide Headquarters At Summit Office Campus in Aliso Viejo 53
Apr 17, 2015: Regarding the Result of Inspection at Terumo CVS Ann Arbor Plant 54
Apr 06, 2015: Terumo and Olympus Expand Interventional System Business Partnership 55
Apr 02, 2015: Terumo announces CE mark approvals for LIFEPEARL and HYDROPEARL microspheres 56
Mar 19, 2015: Scientists at Nelson Laboratories Discover Extractable Positive Control for In Vitro Skin Irritation Testing of Medical Devices 57
Feb 12, 2015: Terumo Establishes a New RD Center for Interventional Business in Southern California, US to Accelerate Worldwide Growth of Interventional Therapeutic Area 58
Section 6 - Appendix 59
Methodology 59
Ratio Definitions 59
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Terumo Corporation, Key Facts 6
Terumo Corporation, Key Employees 7
Terumo Corporation, Key Operational Employees 10
Terumo Corporation, Major Products and Services 11
Terumo Corporation Pipeline Products by Equipment Type 13
Terumo Corporation Number of Pipeline Products by Development Stage 14
Terumo Corporation Pipeline Products Summary by Development Stage 15
Terumo Corporation, History 16
Terumo Corporation, Other Locations 24
Terumo Corporation, Subsidiaries 25
Terumo Corporation, Joint Venture 28
Terumo Corporation, Key Competitors 37
Terumo Corporation, Ratios based on current share price 38
Terumo Corporation, Annual Ratios 39
Terumo Corporation, Interim Ratios 42
Terumo Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 44
Terumo Corporation, Medical Equipment, Deals By Type, 2010 to YTD 2016 45
Terumo Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 46
Terumo Corporation, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 47
Terumo Corporation, Recent Deals Summary 48
Currency Codes 59
Capital Market Ratios 59
Equity Ratios 60
Profitability Ratios 60
Cost Ratios 61
Liquidity Ratios 61
Leverage Ratios 62
Efficiency Ratios 62

List of Figures
Terumo Corporation Pipeline Products by Equipment Type 13
Terumo Corporation Pipeline Products by Development Stage 14
Terumo Corporation, Performance Chart (2012 - 2016) 41
Terumo Corporation, Ratio Charts 43
Terumo Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 44
Terumo Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016 45
Terumo Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 46
Terumo Corporation, Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 47

Companies Mentioned
Merit Medical Systems, Inc.
Medtronic plc
Jarvik Heart, Inc.
F. Hoffmann-La Roche Ltd.
Edwards Lifesciences Corporation
Biotronik SE and Co. KG
Becton, Dickinson and Company
Bayer HealthCare AG
Abiomed, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.